###begin article-title 0
###xml 79 84 <span type="species:ncbi:10090">mouse</span>
gamma-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 111 116 <span type="species:ncbi:9606">human</span>
###xml 614 629 <span type="species:ncbi:10090">transgenic mice</span>
###xml 834 849 <span type="species:ncbi:10090">transgenic mice</span>
###xml 876 881 <span type="species:ncbi:10090">mouse</span>
The role of alpha-synuclein in pathogenesis of familial and idiopathic forms of Parkinson's disease, and other human disorders known as alpha-synucleinopathies, is well established. In contrast, the involvement of two other members of the synuclein family, beta-synuclein and gamma-synuclein, in the development and progression of neurodegeneration is poorly studied. However, there is a growing body of evidence that alpha-synuclein and beta-synuclein have opposite neuropathophysiological effects. Unlike alpha-synuclein, overexpressed beta-synuclein does not cause pathological changes in the nervous system of transgenic mice and even ameliorates the pathology caused by overexpressed alpha-synuclein. To assess the consequences of excess expression of the third family member, gamma-synuclein, on the nervous system we generated transgenic mice expressing high levels of mouse gamma-synuclein under control of Thy-1 promoter. These animals develop severe age- and transgene dose-dependent neuropathology, motor deficits and die prematurely. Histopathological changes include aggregation of gamma-synuclein, accumulation of various inclusions in neuronal cell bodies and processes, and astrogliosis. These changes are seen throughout the nervous system but are most prominent in the spinal cord where they lead to loss of spinal motor neurons. Our data suggest that down-regulation of small heat shock protein HSPB1 and disintegration of neurofilament network play a role in motor neurons dysfunction and death. These findings demonstrate that gamma-synuclein can be involved in neuropathophysiological changes and the death of susceptible neurons suggesting the necessity of further investigations of the potential role of this synuclein in disease.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 286 287 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C1">1</xref>
###xml 392 399 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 512 513 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C2">2</xref>
###xml 514 515 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C7">7</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
The importance of alpha-synuclein in the development and progression of the human disorders known as synucleinopathies is beyond doubt although the exact mechanism of neurodegeneration induced by dysfunction of this protein is the subject of heated debate [for recent reviews see Ref. (1)]. On the other hand, beta-synuclein is believed to be a neuroprotective factor-in several experimental in vivo systems, expression of this protein ameliorated neuronal pathology caused by overexpression of alpha-synuclein (2-7).
###end p 4
###begin p 5
###xml 344 345 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C8">8</xref>
###xml 478 485 459 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 738 739 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C1">1</xref>
###xml 740 741 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C9">9</xref>
###xml 742 744 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C10">10</xref>
###xml 923 931 897 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 933 934 907 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C2">2</xref>
###xml 935 937 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C11">11</xref>
###xml 938 940 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C13">13</xref>
###xml 1044 1052 1010 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1154 1156 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C11">11</xref>
###xml 1157 1159 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C12">12</xref>
###xml 1342 1344 1293 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C14">14</xref>
###xml 1345 1347 1296 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C15">15</xref>
Despite limited information, certain known properties of gamma-synuclein place it structurally and functionally in between the other two members of the synuclein family. For instance, gamma-synuclein adopts a free-state residual secondary structure similar to alpha-synuclein whereas in an extended mode its structure resembles beta-synuclein (8). These structural differences correlate with different propensities of the synucleins to aggregate. Aggregation of alpha-synuclein in vivo is believed to be a crucial event in pathogenesis of these diseases, with intermediates (i.e. soluble oligomers) and final products (i.e. larger, insoluble and immunohistochemically detectable aggregates) playing different but equally important roles (1,9,10). Conversely, a protective function of beta-synuclein seems to correlate with its negligible propensity to aggregate and its ability to retard the aggregation of alpha-synuclein in vitro (2,11-13). gamma-Synuclein is able, albeit less efficiently than alpha-synuclein, to aggregate and form fibrils in vitro. However, like beta-synuclein, it has also been shown to inhibit the aggregation of alpha-synuclein (11,12). In contrast to alpha-synuclein, acute overexpression of gamma-synuclein does not induce death of cultured neurons but perturbs their neurofilament network by an unknown mechanism (14,15).
###end p 5
###begin p 6
###xml 258 260 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C16">16</xref>
###xml 261 263 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C18">18</xref>
###xml 375 377 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C19">19</xref>
###xml 378 380 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C21">21</xref>
###xml 564 566 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C16">16</xref>
###xml 567 569 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C22">22</xref>
###xml 570 572 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C26">26</xref>
###xml 445 450 <span type="species:ncbi:9606">human</span>
While alpha-synuclein is the major component of Lewy bodies and other histopathological hallmarks of synucleinopathies, neither beta-synuclein nor gamma-synuclein have been found in these structures. Nonetheless, changes in their expression or distribution (16-18) and accumulation of these proteins in unconventional histopathological lesions within neurons and axons (Refs 19-21 and our unpublished observations) have been observed in several human neurodegenerative disorders as well as certain transgenic or pharmacological animal models of neurodegeneration (16,22-26). Therefore, it is tempting to speculate that accumulation and aggregation of gamma-synuclein might be a causative factor in the development of certain, yet to be identified, types of neurological disorders.
###end p 6
###begin p 7
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
###xml 180 195 <span type="species:ncbi:10090">transgenic mice</span>
To test whether increased and/or ectopic expression of mouse gamma-synuclein could trigger neurohistopathological changes and phenotypes typical for synucleinopathies, we produced transgenic mice with pan-neuronal overexpression of this protein. Animals expressing high levels of gamma-synuclein develop severe and fatal neurological disease associated with aggregation of the overexpressed protein and its deposition in cytoplasmic and axonal lesions.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
Production of transgenic animals and analysis of transgene expression
###end title 9
###begin p 10
###xml 151 152 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 266 268 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C27">27</xref>
###xml 269 271 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C30">30</xref>
###xml 292 293 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C5">5</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
###xml 296 300 <span type="species:ncbi:10090">Mice</span>
###xml 355 360 <span type="species:ncbi:10090">mouse</span>
###xml 462 466 <span type="species:ncbi:10090">Mice</span>
Transgenic mice expressing elevated levels of mouse wild-type gamma-synuclein were generated using the Thy-1 neuron-specific expression cassette (Fig. 1A) that we and others have used previously for generating lines expressing high levels of either alpha-synuclein (27-30) or beta-synuclein (5). Mice from one line, Thy1mgammaSN, expressed high levels of mouse gamma-synuclein throughout the nervous system and developed an age-dependent neurological phenotype. Mice of a second line with lower levels of the transgene expression did not develop a noticeable phenotype and were excluded from this study.
###end p 10
###begin p 11
###xml 65 66 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 230 231 222 223 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 770 771 744 745 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1167 1168 1129 1130 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 47 62 <span type="species:ncbi:10090">transgenic mice</span>
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 748 752 <span type="species:ncbi:10090">mice</span>
###xml 1416 1420 <span type="species:ncbi:10090">mice</span>
Expression of gamma-synuclein in wild-type and transgenic mice. (A) A map of DNA fragment used for producing transgenic animals. A mouse gamma-synuclein cDNA fragment was inserted between exons II and IV of the mouse Thy-1 gene. (B) Expression of gamma-synuclein mRNA in neuronal tissues of wild-type and transgenic animals measured by quantitative real-time RT-PCR. Bar charts show the fold gamma-synuclein mRNA level increase (mean +/- SEM) in the spinal cord of homozygous and heterozygous 8-week-old Thy1mgammaSN mice compared with the level in the trigeminal ganglion of newborn wild-type mice (top chart) and in the DRG and spinal cord of homozygous 12-month-old Thy1mgammaSN mice compared with the level in the DRG of 12-month-old wild-type mice (bottom chart). (C) Western blot analysis of gamma-synuclein in the spinal cord of 1-year-old wild-type and homozygous Thy1mgammaSN animals. The top panel shows a normalization western blot simultaneously probed with antibodies against GAPDH and gamma-synuclein. The same undiluted wild-type samples and 1:1000, 1:500 or 1:250 diluted transgenic samples were analysed on a western blot shown in the bottom panel. (D) Western blot analysis of three synucleins in the spinal cord and brain regions of 1-year-old wild-type and Thy1mgammaSN transgenic (hemi- and homozygous) animals. More gamma-synuclein accumulates in neuronal tissues of homozygous than hemizygous mice but a ladder of multimeric gamma-synuclein-positive bands is not observed even on overexposed western blots (top panels).
###end p 11
###begin p 12
###xml 756 757 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 1370 1371 1350 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 1471 1473 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C31">31</xref>
###xml 1661 1662 1625 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 1697 1698 1661 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 1755 1756 1719 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 1870 1872 1830 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C32">32</xref>
###xml 2068 2069 2024 2025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 1210 1214 <span type="species:ncbi:10090">mice</span>
###xml 1496 1500 <span type="species:ncbi:10090">mice</span>
Transgenic mice were produced on a pure genetic background and the colony was maintained by backcrossing hemizygous Thy1mgammaSN mice with C57Bl6 mice. These hemizygous animals were indistinguishable from their wild-type littermates during the first year of their life. Later most of these mice developed a clasping reflex, abnormal posture and gait, as well as other signs of motor dysfunction (see below). In an attempt to augment the pathology we bred Thy1mgammaSN mice to homozygosity. This resulted in an approximate doubling of the transgene expression levels, which in dorsal root ganglia (DRG) of 12-month-old mice reached the level that was approximately seven times higher than the level of endogenous gamma-synuclein mRNA in these ganglia (Fig. 1B). Offspring from intercrosses of hemizygous parents showed a normal Mendelian distribution of genotypes. Homozygous animals appeared normal during the first few months of life despite a very high level of gamma-synuclein mRNA expression throughout their nervous system. For instance, in the spinal cord of young adult homozygous transgenic animals, the level of this mRNA was approximately 16 times higher than in the trigeminal ganglion of wild-type mice that was used for reference due to the high endogenous level of gamma-synuclein mRNA expression and homogeneity of cell population in this structure (Fig. 1B, top panel). In the spinal cord of wild-type animals, only motor neurons express gamma-synuclein (31), but in Thy1mgammaSN mice, motorneurons and additional types of spinal neurons expressed gamma-synuclein, which explains, in part, the robust increase of both gamma-synuclein mRNA (Fig. 1B, bottom panel) and protein (Fig. 1C and D) levels. The same applied to other regions (Fig. 1D and data not shown) where endogeneous gamma-synuclein expression is restricted to certain neuronal populations (32) but the transgene is expressed in the majority of neurons. Substantial accumulation of gamma-synuclein did not affect the levels of expression of the other two members of synuclein family (Fig. 1D).
###end p 12
###begin title 13
###xml 108 123 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression of gamma-synuclein is associated with a severe neurological phenotype and early lethality of transgenic mice
###end title 13
###begin p 14
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F2">2</xref>
###xml 510 511 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F2">2</xref>
###xml 877 878 877 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F2">2</xref>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 706 721 <span type="species:ncbi:10090">transgenic mice</span>
###xml 753 758 <span type="species:ncbi:10090">mouse</span>
###xml 833 837 <span type="species:ncbi:10090">mice</span>
The health of homozygous animals started to deteriorate substantially from the age of 6-9 months. The first signs of pathology were similar to those observed in the older hemizygous mice, including clasping reflex, hunchback posture and abnormal gait (Fig. 2A-C and ). In contrast to hemizygous animals, clinical signs of pathology in homozygous animals progressed rapidly with all animals developing pareses of their limbs by the age of 9-16 months followed by paralyses and loss of the righting reflex (Fig. 2D). At this stage, the animals were sacrificed to prevent further suffering. Typically, the paraparesis of the forelimbs became obvious earlier than that of the hindlimbs. Lifespan of homozygous transgenic mice was also limited; not a single mouse survived beyond the age of 16 months in two independent cohorts (total 74 mice) housed in two animal facilities (Fig. 2E).
###end p 14
###begin p 15
###xml 218 219 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 246 247 242 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 438 439 430 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 525 526 517 518 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 570 571 562 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 615 616 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 661 662 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 710 711 694 695 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 103 118 <span type="species:ncbi:10090">transgenic mice</span>
###xml 336 351 <span type="species:ncbi:10090">transgenic mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
Transgenic animals develop pathology that leads to premature death. Typical appearance of Thy1mgammaSN transgenic mice at the initial stage of pathology development with clasping of all limbs when hanging by the tail (A) and a hunchback posture (B). Examples of severe gait abnormality in 9- and 12-month-old homozygous gamma-synuclein transgenic mice detected by the footprint test. Forefeet prints are blue and hindfeet prints are red (C). At the advanced stage of pathology, the righting reflex is substantially impaired (D). Kaplan-Meier plot of wild-type (squares, n = 49), hemizygous Thy1mgammaSN (triangles, n = 87) and homozygous Thy1mgammaSN (circles, n = 74) mice survival over the 26 months period (E).
###end p 15
###begin p 16
###xml 271 272 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F3">3</xref>
###xml 429 430 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F3">3</xref>
###xml 689 690 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F3">3</xref>
###xml 939 940 927 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F3">3</xref>
###xml 180 184 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
###xml 718 722 <span type="species:ncbi:10090">mice</span>
###xml 1107 1111 <span type="species:ncbi:10090">mice</span>
The onset and progression of motor dysfunction was quantified using several different tests. Balance and coordination were already significantly impeded in homozygous Thy1mgammaSN mice younger than 6 months before they displayed obvious clinical signs of pathology (Fig. 3 and ). Their ability to turn on an 11 mm diameter beam and their performance on a constant speed rotarod were both compromised by the age of 4 months (Fig. 3A and ). Using the accelerating rotarod test, it was possible to demonstrate motor impairments as early as at 2 months of age. At this time point the homozygous Thy1mgammaSN mice were indistinguishable from wild-type mice by any other criteria examined (Fig. 3B). Hemizygous Thy1mgammaSN mice developed a similar motor dysfunction but with a much greater latency and slower progression. This is exemplified by their performance on the rotarod that only declined significantly after the age of 18 months (Fig. 3). In the footprint test, the length of stride of hemizygous 18-month-old animals was significantly shorter than that of their wild-type littermates, while homozygous mice already showed this impairment at the age of 6 months ( and data not shown). The horizontal beam test was most sensitive for detecting early signs of motor deficit in hemizigous Thy1mgammaSN animals; their ability to perform both parts of the task was already obviously compromised at the age of 12 months ().
###end p 16
###begin p 17
###xml 159 160 155 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 179 180 175 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 436 437 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 456 457 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
Rotarod performance of gamma-synuclein transgenic mice. Groups of mice of different ages and genotypes were tested on Ugo Basile rotarod using constant speed (A) or accelerating (B) modes as described in Material and methods. Line graphs show mean +/- SEM of latency to fall for wild-type (diamonds), hemizygous Thy1mgammaSN (squares) and homozygous (triangles) Thy1mgammaSN mice at different age. Statistically significant difference (P < 0.01, Student's t-test) in performance between transgenic and wild type groups at particular age is denoted by asterisks.
###end p 17
###begin p 18
###xml 336 338 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C27">27</xref>
###xml 339 341 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C30">30</xref>
###xml 342 344 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C33">33</xref>
###xml 345 347 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C39">39</xref>
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
###xml 68 83 <span type="species:ncbi:10090">transgenic mice</span>
###xml 240 245 <span type="species:ncbi:9606">human</span>
In summary, pan-neuronal overexpression of mouse gamma-synuclein in transgenic mice was associated with a progressive age- and gene dose-dependent motor phenotype that recapitulates phenotypes described earlier for several lines expressing human alpha-synuclein under control of the same Thy-1 promoter or other pan-neuronal promoters (27,30,33-39).
###end p 18
###begin title 19
###xml 73 88 <span type="species:ncbi:10090">transgenic mice</span>
Aggregation and fibrillation of gamma-synuclein in the nervous system of transgenic mice
###end title 19
###begin p 20
###xml 91 106 <span type="species:ncbi:10090">transgenic mice</span>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
It was feasible to suggest that pathological changes in the nervous system of Thy1mgammaSN transgenic mice would also be similar to the changes observed in the nervous system of alpha-synuclein transgenic animals and might be accompanied by aggregation of gamma-synuclein in neurons and their processes. Therefore, we looked for signs of gamma-synuclein aggregation throughout the nervous system of homozygous Thy1mgammaSN mice that developed obvious pathology.
###end p 20
###begin p 21
###xml 120 122 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C31">31</xref>
###xml 430 432 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C32">32</xref>
###xml 882 883 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F4">4</xref>
###xml 1004 1005 976 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F4">4</xref>
###xml 1085 1086 1057 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F4">4</xref>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 559 564 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical analysis of Thy1mgammaSN brain and spinal cord sections stained with highly specific SK23 antibody (31) revealed increased production of gamma-synuclein in many neurons expressing endogenous gamma-synuclein as well as ectopic production in other neurons normally devoid of this protein. In contrast to the predominantly neuritic localization of endogenous gamma-synuclein in the brain of adult wild-type mice (32), overproduced protein also accumulated in the neuronal cell bodies (). Although immunostaining in the majority of transgenic mouse brain neurons was diffusely distributed throughout the cytoplasm, in subsets of neurons, we detected gamma-synuclein-positive cytoplasmic inclusions which, in some cases, were clearly eosinophilic and also showed some remarkable resemblance to the alpha-synuclein-positive structures seen in Lewy body diseases (Fig. 4A and ). However, much more typical was the presence of gamma-synuclein-positive spheroids and dystrophic neurites (Fig. 4A and ) that were not seen in the nervous system of wild-type littermates (Fig. 4A and data not shown).
###end p 21
###begin p 22
###xml 154 155 146 147 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 764 765 740 741 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 949 950 921 922 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 83 98 <span type="species:ncbi:10090">transgenic mice</span>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
###xml 259 274 <span type="species:ncbi:10090">transgenic mice</span>
###xml 942 946 <span type="species:ncbi:10090">mice</span>
###xml 1080 1085 <span type="species:ncbi:10090">mouse</span>
gamma-Synuclein-positive aggregates and fibrils in the spinal cord of 12-month-old transgenic mice detected by anti-mouse gamma-synuclein SK23 antibody. (A) Immunostained transverse sections through the spinal cord of wild-type and homozygous gamma-synuclein transgenic mice. Higher magnification images of the ventral horn region are shown on lower panels, scale bars = 50 microm. A gamma-synuclein-positive cytoplasmic inclusion (further magnified in the left inset) is indicated by the small arrowheads, spheroids by large arrowheads, dystrophic and ballooned neurites by small and large arrows, correspondingly. The right insert shows a hematoxylin and eosin-stained spinal cord motor neuron with an eosinophilic cytoplasmic inclusion, scale bar = 20 microm. (B) Western blot analysis of gamma-synuclein in high salt (HS), HS/Triton X-100 (HS/T), RIPA- and SDS-soluble fractions of the spinal cord of wild-type, hemizygous and homozygous mice. (C) Immuno-electron microscopy detection of gamma-synuclein fibrils in a sarcosyl-insoluble fraction of the homozygous Thy1mgammaSN mouse spinal cord.
###end p 22
###begin p 23
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F4">4</xref>
###xml 776 777 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F4">4</xref>
###xml 963 964 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F4">4</xref>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 1042 1047 <span type="species:ncbi:10090">mouse</span>
These abnormal structures were observed throughout the nervous system but were most abundant in the spinal cord (Fig. 4A), which is consistent with the observed clinical pattern of pathology. Therefore, the spinal cord was used to determine whether aggregated and fibrillated forms of gamma-synuclein were present in neuronal tissues of animals overexpressing this protein. Sequential fractionation of the spinal cord tissues demonstrated that, in contrast to endogenous gamma-synuclein, which was completely soluble in salt/non-ionic detergent buffers, a substantial fraction of gamma-synuclein in the spinal cord of Thy1mgammaSN mice remained insoluble after extraction with these solutions but could be partially solubilized in the ionic detergent-containing buffers (Fig. 4B) or in formic acid (data not shown). Immuno-electron microscopy of sarcosyl-insoluble material revealed the presence of filaments decorated with antibody against gamma-synuclein (Fig. 4C). These results demonstrate that increased expression of gamma-synuclein in mouse neurons can cause aggregation and fibrillation of this protein followed by formation of large intracellular inclusions.
###end p 23
###begin title 24
###xml 37 52 <span type="species:ncbi:10090">transgenic mice</span>
Histopathology in the spinal cord of transgenic mice
###end title 24
###begin p 25
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F5">5</xref>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F5">5</xref>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
Amyloid-like inclusions were detected by Congo Red (Fig. 5B-D) or thioflavine S (data not shown) staining of spinal cord or brain tissue of hemi- and homozygous mice, even at a stage when clinical signs of pathology were mild (only clasping reflex). The number of the Congo Red-positive inclusions substantially increased as disease progressed (Fig. 5E).
###end p 25
###begin p 26
###xml 169 170 165 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 204 205 196 197 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 273 274 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 340 341 324 325 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 515 516 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 788 796 762 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 816 817 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 851 852 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 55 70 <span type="species:ncbi:10090">transgenic mice</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 197 202 <span type="species:ncbi:10090">mouse</span>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 304 309 <span type="species:ncbi:10090">mouse</span>
Amyloid deposits in the spinal cord of gamma-synuclein transgenic mice. Representative images of Congo Red-stained spinal cord sections of 12-month-old wild-type mouse (A), hemizygous Thy1mgammaSN mouse (B), homozygous Thy1mgammaSN mouse at the advance stage of pathology (C) and homozygous Thy1mgammaSN mouse with mild signs of pathology (D) are shown. Scale bar = 200 microm for all main panels and 25 microm for all insets. The bar chart shows mean +/- SEM. of the number of deposits per randomly selected 0.1 mm2 area of the spinal cord gray matter. Sections for counting [104 for (A), 121 for (B), 93 for (C) and 72 for (D)] were randomly selected throughout the length of cervical, thoracic and lumbar parts of the spinal cord of at least four animals per group. One-way ANOVA with post hoc Fisher's protected t-test demonstrated significant (**P < 0.01) difference between all four experimental groups.
###end p 26
###begin p 27
###xml 320 321 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F6">6</xref>
###xml 513 514 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F6">6</xref>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
Neuronal degeneration is commonly associated with the activation of microglia and astroglia in affected regions of the nervous system. A large number of GFAP-positive cells with morphology typical for activated astrocytes were found in the spinal cord gray matter of severely affected homozygous Thy1mgammaSN mice (Fig. 6A). The level of GFAP was also substantially increased in the spinal cord tissue of homozygous and, to a lesser extent, age-matched hemizygous animals without obvious signs of pathology (Fig. 6B) but not in the spinal cord of young homozygous mice. However, using antibodies against two different markers, Iba1 and CD11b, we failed to detect clear signs of microglia activation (data not shown).
###end p 27
###begin p 28
###xml 103 104 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 318 319 306 307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 517 518 501 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 775 776 755 756 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 85 100 <span type="species:ncbi:10090">transgenic mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 415 430 <span type="species:ncbi:10090">transgenic mice</span>
###xml 609 614 <span type="species:ncbi:10090">mouse</span>
###xml 846 851 <span type="species:ncbi:10090">mouse</span>
Astrogliosis and ubiquitin-positive inclusions in the spinal cord of gamma-synuclein transgenic mice. (A) Transverse sections through the spinal cord of wild-type and severely affected homozygous Thy1mgammaSN mice immunostained for GFAP. Higher magnification images are shown on lower panels, scale bars = 20 microm. (B) Western blot of total protein extracts from 12-month-old wild-type, hemizygous and homozygous transgenic mice probed with antibodies against gamma-synuclein, GFAP and GAPDH as a loading control. (C) Transverse sections through the spinal cord of severely affected homozygous Thy1mgammaSN mouse immunostained for ubiquitin. Boxed areas of gray and white matter are shown at higher magnification on the right top and right bottom panels, correspondingly. (D) Double immunofluorescent staining of severely affected Thy1mgammaSN mouse spinal cord section with antibodies against ubiquitin (green) and gamma-synuclein (red). Examples of dystrophic neuritis and spheroids positive only for gamma-synuclein are marked with large arrows, positive only for ubiquitin-with small arrows and positive for both proteins-with arrowheads. Scale bar = 50 microm.
###end p 28
###begin p 29
###xml 260 261 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F6">6</xref>
###xml 401 402 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F6">6</xref>
###xml 573 574 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F1">1</xref>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
###xml 822 826 <span type="species:ncbi:10090">mice</span>
Another common feature of synucleinopathies is the presence of ubiquitin-positive inclusions in affected regions of the nervous system. In the spinal cord of gamma-synuclein transgenic animals, we detected multiple abnormal ubiquitin-positive structures (Fig. 6C). However, double immunofluorescence revealed only partial overlap between gamma-synuclein-positive and ubiquitin-positive profiles (Fig. 6D). Furthermore, western blot analysis did not reveal gamma-synuclein-laddered staining patterns reminiscent of different degrees of ubiquitination (for example, see Fig. 1D). Therefore, most of the aggregated gamma-synuclein in the spinal cord of Thy1mgammaSN mice are probably not ubiquitinated, but ubiquitin and/or some ubiquitinated proteins are present in the inclusions that appear in the nervous system of these mice.
###end p 29
###begin title 30
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Loss of motor neurons in the spinal cord of transgenic mice
###end title 30
###begin p 31
###xml 145 146 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F7">7</xref>
###xml 307 308 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F7">7</xref>
###xml 540 541 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F7">7</xref>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
The emergence of pathological inclusions and astrogliosis in Thy1mgammaSN mice coincides with the loss of motor neurons in the spinal cord (Fig. 7). Twelve-month-old homozygous animals with severe motor impairments possessed less than 40% of their wild-type littermates spinal motor neuron complement (Fig. 7E). Age-matched hemizygous and homozygous mice that developed milder motor impairment (clasping reflex and pareses of one limb but normal righting, for example see ) also displayed motor neuron loss but to a far lesser extent (Fig. 7E). Similar results were obtained in cervical, thoracic and lumbar parts of the spinal cord (data not shown).
###end p 31
###begin p 32
###xml 215 216 211 212 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 250 251 242 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 319 320 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 377 378 361 362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 392 393 376 377 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 816 824 798 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 844 845 826 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 879 880 861 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 937 938 919 920 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 92 107 <span type="species:ncbi:10090">transgenic mice</span>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
###xml 278 283 <span type="species:ncbi:10090">mouse</span>
###xml 350 355 <span type="species:ncbi:10090">mouse</span>
###xml 561 566 <span type="species:ncbi:10090">mouse</span>
###xml 1015 1020 <span type="species:ncbi:10090">mouse</span>
###xml 1067 1072 <span type="species:ncbi:10090">mouse</span>
Loss of motor neurons and changes of HSPB1 expression in the spinal cord of gamma-synuclein transgenic mice. Representative images of cresyl fast violet-stained spinal cord sections of 12-month-old wild-type mouse (A), hemizygous Thy1mgammaSN mouse (B), homozygous Thy1mgammaSN mouse at the advance stage of pathology (C) and homozygous Thy1mgammaSN mouse with mild pathology (D) are shown. (E) The bar chart shows mean +/- SEM. of the number of motor neurons per section expressed as percent of the average number of motor neurons per section of the wild-type mouse spinal cord. Sections for counting [160 for (A), 332 for (B), 215 for (C) and 139 for (D)] were randomly selected throughout the length of cervical, thoracic and lumbar parts of the spinal cord of at least four animals per group. One-way ANOVA with post hoc Fisher's protected t-test demonstrated significant (**P<0.01) difference between all four experimental groups. (F) Double immunofluorescent staining of spinal cord sections from a wild-type mouse and severely affected homozygous Thy1mgammaSN mouse with antibodies against neurofilament-L (green) and HSPB1 (red). Scale bar = 20 microm.
###end p 32
###begin p 33
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C40">40</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C44">44</xref>
###xml 833 834 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F7">7</xref>
###xml 1000 1001 996 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F7">7</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 434 439 <span type="species:ncbi:10090">mouse</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 989 993 <span type="species:ncbi:10090">mice</span>
Neurodegeneration in the spinal cord of motor neuron disease patients is often associated with dysfunction of intracellular systems that are responsible for correct folding of protein molecules. Survival of spinal motor neurons seems to rely on molecular chaperons including small heat shock proteins (40-44). Therefore, we used western blot analysis to examine the levels of large (HSP70) and small (HSPB1 also known as HSP27 or, in mouse, HSP25) heat shock proteins in the spinal cords of Thy1mgammaSN mice. While the levels of HSP70 were similar in age-matched transgenic and wild-type animals, the levels of HSPB1 were dramatically increased in all ageing transgenic animals and particularly in those that displayed severe motor impairment (). However, this increase was due to high levels of HSPB1 in activated astrocytes (Fig. 7F and ), whereas in spinal motor neurons of transgenic animals the level of this protein was substantially lower than in spinal motor neurons of wild-type mice (Fig. 7F).
###end p 33
###begin title 34
###xml 59 74 <span type="species:ncbi:10090">transgenic mice</span>
Neurofilaments in the spinal cord and peripheral nerves of transgenic mice
###end title 34
###begin p 35
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C45">45</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C47">47</xref>
###xml 347 349 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C15">15</xref>
###xml 693 694 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 1236 1237 1220 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 421 436 <span type="species:ncbi:10090">transgenic mice</span>
###xml 563 568 <span type="species:ncbi:10090">mouse</span>
###xml 806 811 <span type="species:ncbi:10090">mouse</span>
HSPB1 is thought to be involved in regulation of the neurofilament network assembly in normal motor neurons and its mutant variants affect neurofilament-L (NF-L) aggregation in certain forms of Charcot-Marie-Tooth disease (45-47). An acute overexpression of gamma-synuclein in cultured neurons also perturbs their neurofilament network integrity (15). Therefore, we analysed neurofilaments in the spinal motor neurons of transgenic mice chronically overexpressing gamma-synuclein. Western blot analysis of the non-ionic detergent soluble fraction of Thy1mgammaSN mouse spinal cord revealed not only monomeric full-length 67 kDa NF-L but also distinct lower molecular weight NF-L species (Fig. 8A), possibly products of specific and restricted breakdown that were not seen in similar fractions of wild-type mouse spinal cord tissue. Decrease of these truncated species in the spinal cord of severely affected animals probably reflects loss of neurons that produced them. Overexpressed gamma-synuclein co-immunoprecipitated with soluble NF-L, although substantially less amount of this protein was pulled-down from spinal cord lysates of animals at the advance stages of pathology than from similar lysates of less-affected animals (Fig. 8B).
###end p 35
###begin p 36
###xml 95 96 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 171 172 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 412 413 396 397 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 521 522 501 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 783 784 751 752 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 592 597 <span type="species:ncbi:10090">mouse</span>
###xml 964 968 <span type="species:ncbi:10090">mice</span>
Neurofilaments in the spinal cord and peripheral nerve of gamma-synuclein transgenic animals. (A) Western blot analysis of soluble neurofilament-L in the cytosolic (10 000g supernatant) fraction of the spinal cord of 12-month-old wild-type mice, hemizygous Thy1mgammaSN mice, homozygous Thy1mgammaSN mice with mild clinical signs of pathology and homozygous Thy1mgammaSN mice at the advance stage of pathology. (B) Co-immunoprecipitation of gamma-synuclein and soluble neurofilament-L from the same cytosolic fractions. (C) Double immunofluorescent staining of severely affected Thy1mgammaSN mouse spinal cord section with antibodies against neurofilament-L (green) and gamma-synuclein (red) shows the absence of NF-L accumulation in gamma-synuclein-positive pathological profiles. (D) Substantial reduction of neurofilament-L staining in the ventral horns of the spinal cord (upper panels) and sciatic nerve (lower panels) of 12-month-old homozygous Thy1mgammaSN mice at the advance stage of pathology compared with their wild-type littermates. Scale bars = 20 microm for (C) and 50 microm for (D).
###end p 36
###begin p 37
###xml 221 222 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 374 375 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 479 480 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 668 669 656 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 849 850 833 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDP090F8">8</xref>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:10090">mice</span>
###xml 838 842 <span type="species:ncbi:10090">mice</span>
###xml 1080 1085 <span type="species:ncbi:10090">mouse</span>
Immunostaining of histological sections with antibody against NF-L did not reveal accumulation of this protein in gamma-synuclein-positive or any other pathological profiles in the spinal cord of transgenic animals (Fig. 8C). However, substantial reduction in staining intensity in the spinal cord of Thy1mgammaSN mice when compared with wild-type tissue was observed (Fig. 8C). This reduction was mainly confined to neuronal processes and not the motor neuron cell bodies (Fig. 8D, upper panels). It was even more obvious in longitudinal sections through peripheral nerves of Thy1mgammaSN mice where only thin and wavy neurofilament-positive strings were found (Fig. 8D, lower panels). In addition, severe axonal pathology in the form of multiple nerve fibre swellings was revealed in the sciatic nerve of ageing homozygous Thy1mgammaSN mice (Fig. 8D, lower panels). Similar changes were also observed in tissue sections stained with antibodies against two other neurofilament proteins (data not shown). These results suggest that overexpression of gamma-synuclein in transgenic mouse neurons seriously compromises the organization of neurofilaments in neuronal processes and, consequently, the architecture and function of axons.
###end p 37
###begin title 38
DISCUSSION
###end title 38
###begin p 39
###xml 506 508 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C48">48</xref>
###xml 509 511 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C50">50</xref>
###xml 660 661 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C5">5</xref>
###xml 662 663 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C7">7</xref>
###xml 1111 1118 1070 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 20 35 <span type="species:ncbi:10090">transgenic mice</span>
Previous studies of transgenic mice overexpressing members of the synuclein family have revealed the contrasting effects of alpha-synuclein and beta-synuclein on the development of pathological changes in the nervous system of these animals. High levels of alpha-synuclein in neurons cause a prominent neurological phenotype although the manifestations are variable and dependent on the alpha-synuclein isoform and type of promoter used for production of that particular transgenic line (reviewed in Refs. 48-50). In contrast, overexpression of beta-synuclein does not have a harmful effect on animal health and even counteracts alpha-synuclein neurotoxicity (5-7). These results echo differences in aggregation propensity, cytotoxicity and certain structural features of these two proteins. As discussed in the Introduction, gamma-synuclein has molecular features shared with both alpha- and beta-synuclein. Therefore, it was not possible to predict the consequences of gamma-synuclein overexpression in the nervous system of transgenic animals. Revealing the effects of aberrant expression of gamma-synuclein in vivo is important not only for better understanding of relationships between structure and function within synuclein family. This information would also be valuable for development of new therapeutic approaches to combat synucleinopathies.
###end p 39
###begin p 40
###xml 626 628 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C27">27</xref>
###xml 629 631 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C30">30</xref>
###xml 655 656 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C5">5</xref>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 181 186 <span type="species:ncbi:9606">human</span>
###xml 191 196 <span type="species:ncbi:10090">mouse</span>
###xml 310 315 <span type="species:ncbi:10090">mouse</span>
###xml 384 389 <span type="species:ncbi:10090">mouse</span>
###xml 447 462 <span type="species:ncbi:10090">transgenic mice</span>
###xml 490 495 <span type="species:ncbi:10090">mouse</span>
###xml 896 911 <span type="species:ncbi:10090">transgenic mice</span>
###xml 936 940 <span type="species:ncbi:10090">mice</span>
No disease-associated mutations of gamma-synuclein gene or obvious cases of idiopathic human gamma-synucleinopathies have been reported so far and the amino acid similarity between human and mouse proteins is high. Taking these facts into consideration, we decided to create a simple homologous model in which mouse gamma-synuclein was overexpressed in the majority of neurons of the mouse nervous system. To achieve this we produced Thy1mgammaSN transgenic mice, expressing high levels of mouse gamma-synuclein under control of the Thy-1 promoter cassette that has previously been used for producing several alpha-synuclein (27-30) and a beta-synuclein (5) transgenic animal lines. In relatively homogeneous populations of neurons that normally express gamma-synuclein, for example the DRG, there was approximately a 7-fold increase of gamma-synuclein mRNA expression in homozygous Thy1mgammaSN transgenic mice compared with wild-type mice.
###end p 40
###begin p 41
###xml 707 714 683 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 718 726 694 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 14 29 <span type="species:ncbi:10090">transgenic mice</span>
###xml 432 437 <span type="species:ncbi:10090">mouse</span>
In homozygous transgenic mice, gamma-synuclein aggregates and accumulates in abnormal structures within neuronal cell bodies and neurites. These gamma-synuclein-positive structures resemble pathological hallmarks of synucleinopathies, namely dystrophic, beaded and ballooned neurites, spheroids, and even, occasionally, Lewy bodies. Like aggregated alpha-synuclein, aggregated gamma-synuclein could not be extracted from transgenic mouse neural tissues using non-ionic detergents, but is partially soluble in sarcosyl-containing buffers. At least a fraction of aggregated gamma-synuclein forms linear fibrils that are structurally similar, although not identical to products of alpha-synuclein fibrillation in vivo or in vitro.
###end p 41
###begin p 42
###xml 209 211 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C35">35</xref>
###xml 212 214 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C37">37</xref>
###xml 215 217 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C38">38</xref>
###xml 218 220 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C51">51</xref>
###xml 221 223 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C55">55</xref>
###xml 1802 1804 1746 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C56">56</xref>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 192 207 <span type="species:ncbi:10090">transgenic mice</span>
###xml 462 467 <span type="species:ncbi:10090">mouse</span>
###xml 638 653 <span type="species:ncbi:10090">transgenic mice</span>
###xml 930 945 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1289 1304 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1657 1665 <span type="species:ncbi:9606">patients</span>
###xml 1709 1724 <span type="species:ncbi:10090">transgenic mice</span>
Multimeric forms of alpha-synuclein are commonly detected on western blots of SDS-soluble proteins extracted from neural tissues of patients suffered from synucleinopathies or alpha-synuclein transgenic mice (35,37,38,51-55). These higher molecular weight bands represent either SDS-resistant alpha-synuclein oligomers or ubiquinated forms of the protein. We did not observe similar concatomeric gamma-synuclein species in extracts of gamma-synuclein transgenic mouse brain or spinal cord. This might suggest that the oligomeric intermediates of gamma-synuclein aggregates are either not accumulating to a significant level in neurons of transgenic mice or that they are readily solubilized to monomeric gamma-synuclein in SDS-containing buffers. It also suggests that even aggregated gamma-synuclein is rarely ubiquitinated, which is consistent with our observation that gamma-synuclein-positive inclusions in the spinal cord of transgenic mice often do not co-localize with ubiquitin-positive structures. The most probable explanation of our results is that ubiqutination is neither required for nor accompanies gamma-synuclein aggregation but ubiquitin or certain ubiquitinated proteins may accumulate in pathological inclusions. Moreover, pathological changes in the nervous system of transgenic mice may trigger secondary events, including aggregation of ubiquitinated proteins and formation of ubiquitin-positive/gamma-synuclein-negative inclusions that we have observed on double-immunostained sections of the spinal cord. Similar partial overlap of alpha-synuclein and ubiquitin staining patterns has been found previously in the nervous systems of patients with synucleinopathies and alpha-synuclein transgenic mice, though ubiquinated alpha-synuclein is relatively abundant in these tissues (56).
###end p 42
###begin p 43
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 71 86 <span type="species:ncbi:10090">transgenic mice</span>
###xml 232 247 <span type="species:ncbi:10090">transgenic mice</span>
The common features of alpha-synuclein pathology in human patients and transgenic mice are abundant amyloid deposits and activated glial cells in affected areas of the nervous system. In the brain and spinal cord of gamma-synuclein transgenic mice, we also observed multiple amyloid (Congo Red- and Thioflavin S-positive) deposits and prominent astrogliosis, but no activated microglia was detected.
###end p 43
###begin p 44
###xml 317 319 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C27">27</xref>
###xml 320 322 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C29">29</xref>
###xml 323 325 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C57">57</xref>
###xml 118 122 <span type="species:ncbi:10090">mice</span>
###xml 227 242 <span type="species:ncbi:10090">transgenic mice</span>
Although all pathological changes described above were observed throughout the central nervous system of Thy1mgammaSN mice, the spinal cord was noticeably more affected than any other region, which is similar to the reports on transgenic mice expressing alpha-synuclein under control of the same Thy-1 promoter (Refs 27,29,57 and our unpublished observations). This probably reflects the higher sensitivity of spinal cord neurons, particularly motor neurons, to high levels of both members of the synuclein family.
###end p 44
###begin p 45
###xml 62 77 <span type="species:ncbi:10090">transgenic mice</span>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
The ultimate consequence of gamma-synuclein overexpression in transgenic mice is death of motor neurons. Correspondingly, these mice display clinical signs typical for motor neuron disease, namely a gradual development of motor deficit followed by pareses and paralyses, which are most obvious in limb muscles. At this terminal stage of the disease, gamma-synuclein transgenic animals lose more than 60% of ventral horn motor neurons.
###end p 45
###begin p 46
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
The development of neurological phenotype and histopathological findings in our mice suggests that pan-neuronal overexpression of gamma-synuclein in mice could trigger pathological changes typical for synucleinopathies and most apparent in the spinal cord. The burden of pathology increases with age, which leads to a gradual loss of spinal motor neurons and the development of motor dysfunction. The onset, penetrance and degree of neuropathology directly correlate with the level of transgene expression because the hemizygous animals, which express 50% less transgenic gamma-synuclein than the homozygous animals, develop clinical signs later in their life and show less pronounced histopathological changes in their nervous system.
###end p 46
###begin p 47
###xml 699 701 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C58">58</xref>
###xml 702 704 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C61">61</xref>
###xml 894 901 890 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 924 926 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C45">45</xref>
###xml 927 929 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C62">62</xref>
###xml 930 932 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C67">67</xref>
###xml 1457 1459 1441 1443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C15">15</xref>
###xml 184 199 <span type="species:ncbi:10090">transgenic mice</span>
###xml 258 264 <span type="species:ncbi:9606">humans</span>
###xml 1006 1011 <span type="species:ncbi:10090">mouse</span>
###xml 1255 1270 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1728 1732 <span type="species:ncbi:10090">mice</span>
One intriguing question is which molecular and cellular processes previously linked to the development of neurodegeneration become compromised in the nervous system of gamma-synuclein transgenic mice? Recent studies on the mechanisms of neurodegeneration in humans and in various model organisms demonstrate that simultaneous dysfunction of several systems safeguarding cell homeostasis is required for the development of a full-scale pathology. However, some types of neurons are particularly sensitive to dysfunction in certain intracellular systems. Pathogenesis of motor neuron diseases often involves disruption of neurofilament networks in motor neuron cell bodies and axons (reviewed in Refs 58-61). While this disruption could be triggered by various mechanisms, in the majority of cases changes in the structure or metabolism of NF-L, a subunit required for assembly of neurofilaments in vivo, play a crucial role (45,62-67). We have demonstrated that chronic overexpression of gamma-synuclein in mouse motor neurons leads to substantial depletion of neurofilaments in neuronal processes. This might be an essential event in pathogenesis of axonal pathology in peripheral nerves and consequent development of motor dysfunction in gamma-synuclein transgenic mice. This result is consistent with our previous findings that acute overexpression of gamma-synuclein affects neurofilament network integrity in cultured neurons, particularly their axons (15). The exact mechanism of the disruptive effect of overexpressed gamma-synuclein on neurofilaments remains to be elucidated but its ability to interact with soluble NF-L and accumulation of abnormal NF-L-reactive soluble polypeptides in the spinal cord of Thy1mgammaSN mice suggest that normal homeostasis, including transport of NF-L to axons, might be at least partially prevented by trapping this protein in complexes with gamma-synuclein and/or abnormal degradation. Disruption of axonal neurofilaments follows the reduction of NF-L axonal traffic. Moreover, truncated NF-L species could also affect neurofilament assembly and/or stability.
###end p 47
###begin p 48
###xml 189 191 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C67">67</xref>
###xml 701 703 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C40">40</xref>
###xml 704 706 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C44">44</xref>
###xml 786 788 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C45">45</xref>
###xml 789 791 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C47">47</xref>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 221 236 <span type="species:ncbi:10090">transgenic mice</span>
###xml 830 845 <span type="species:ncbi:10090">transgenic mice</span>
###xml 869 874 <span type="species:ncbi:10090">mouse</span>
Some histopathological changes observed in Thy1mgammaSN mice, including astrocytosis and loss of motor neurons and their axons, are similar to those observed in aged NF-L null mutant mice (67). However in gamma-synuclein transgenic mice, the pathological phenotype develops much earlier and is substantially more severe. This suggests that, in addition to the disrupted neurofilament network, other intracellular systems are also compromised in the motor neurons of these animals. Molecular chaperons belonging to the family of heat shock proteins play an important protective role in motor neurons. These cells seem to be particularly vulnerable to dysfunction of the small heat shock protein HSPB1 (40-44) and mutations of the HSPB1 gene cause certain types of motor neuron diseases (45-47). In motor neurons of gamma-synuclein transgenic mice, the level of HSP25, a mouse ortholog of HSPB1, is substantially reduced, potentially compromising the survival of these cells.
###end p 48
###begin p 49
###xml 30 45 <span type="species:ncbi:10090">transgenic mice</span>
###xml 125 140 <span type="species:ncbi:10090">transgenic mice</span>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
Although some alpha-synuclein transgenic mice develop similar clinical signs of the spinal cord pathology to gamma-synuclein transgenic mice, neither down-regulation of HSPB1 nor changes of the neurofilament network in their motor neurons has been reported. Taken together with other data, this suggests that diverse but partially overlapping mechanisms underlie development of pathology in these two mouse models.
###end p 49
###begin p 50
###xml 41 56 <span type="species:ncbi:10090">transgenic mice</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 459 464 <span type="species:ncbi:9606">human</span>
In conclusion, we have demonstrated that transgenic mice expressing high levels of gamma-synuclein in their neurons develop a severe neurodegenerative pathology. It is feasible that, under certain conditions, gamma-synuclein could be involved in the development of pathological changes in human neurons. Further studies on the role of this synuclein in normal and degenerating neurons might therefore provide additional insight into the mechanisms leading to human neurodegenerative diseases.
###end p 50
###begin title 51
MATERIALS AND METHODS
###end title 51
###begin title 52
Generation of transgenic animals
###end title 52
###begin p 53
###xml 129 131 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C31">31</xref>
###xml 173 176 169 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 196 199 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 258 261 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 347 350 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 396 398 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C27">27</xref>
###xml 507 510 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 830 833 818 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Thy</italic>
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
###xml 969 974 <span type="species:ncbi:10090">mouse</span>
A fragment of mouse gamma-synuclein cDNA including 34 bp of 5'-UTR and 64 bp of 3'-UTR was PCR amplified using pD53 plasmid DNA (31) as a template and oligonucleotides with XhoI linkers (mgammaSN XhoI-F: 5'-CTACTGTCCGCTCGAGCTTGCAGCAGCCAGGTTC-3' and mgammaSN XhoI-R: 5'-CTACTGTCCGCTCGAGGCCTTCTAGTCTTCTCCAC-3') to facilitate subsequent cloning into XhoI site of Thy-1 promoter plasmid 323-pTSC21k (27). The fragment for microinjecting mouse oocytes was isolated by digestion of the resulting plasmid DNA with NotI. Transgenic founders were produced on C57Bl6 genetic background. Animals positive for transgene expression were crossed with C57Bl6 wild-type mice. Transgenic and wild-type animals were identified by PCR analysis of DNA from ear biopsies. The presence of a 1 kb product in the amplification reaction with primers HP45 ThyI f2 (5'-ACACCCCTAAAGCATACAGTCAGACC-3') and HP84 m gammaSN (5'-GGCCTTCTAGTCTTCTCCACTCTTG-3') indicated the presence of transgene in the mouse genome. Experimental cohorts were formed from litters produced by intercrossing hemizygous animals. Hemi- and homozygous animals were discriminated by quantitative real-time PCR analysis of DNA from ear biopsies and verified by analytical backcrossing followed by offspring genotyping. All animal work was carried in accordance with the United Kingdom Animals (Scientific Procedures) Act (1986).
###end p 53
###begin title 54
Motor performance tests
###end title 54
###begin title 55
Rotarod tests
###end title 55
###begin p 56
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C68">68</xref>
###xml 232 237 <span type="species:ncbi:10090">mouse</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
Animals were tested on Ugo Basile 7650 rotarod at 2, 4, 6, 9, 12, 18 and 24 months of age. A constant (24 rpm) speed test was carried out for 4 min and accelerating (4-40 rpm) speed test for 5 min as described previously (68). Each mouse was tested three times in each mode with at least 30 min rest between trials. The mean of latency to fall for these three trials was included in final statistics. Eleven wild type, 12 hemizygous and 13 homozygous mice were tested at 2 months: 28, 27 and 21, at 4 months; 35, 40 and 23, at 6 months; 34, 36 and 23, at 9 months; 25, 26 and 14, at 12 months of age. No homozygous animals survived beyond 16 months therefore at this age and at 24 months only wild-type (12 and 15, respectively) and hemizygous (21 and 15, respectively) animals were tested.
###end p 56
###begin title 57
Horizontal beam test
###end title 57
###begin p 58
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
Animal coordination was tested on an 11 mm diameter and 50 cm long horizontal wooden rod at 4, 6, 9 and 12 months of age. A mouse was placed at the free hanging end of the rod facing its end. The ability to turn 180degrees and to reach an escape black box at the other end of the rod was recorded.
###end p 58
###begin title 59
Footprint test
###end title 59
###begin p 60
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C69">69</xref>
###xml 133 138 <span type="species:ncbi:10090">mouse</span>
Animals were trained to run along a narrow passage lined with a strip of white paper before carrying out the test run. For this run, mouse forefeet were coated with blue ink and hindfeet with red ink. Different parameters of the stride were measured and analysed as described previously (69).
###end p 60
###begin title 61
RNA expression analysis
###end title 61
###begin p 62
###xml 982 995 954 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;CT</sup>
###xml 1028 1030 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C70">70</xref>
Total RNA from various regions of the nervous system was extracted using RNAEasy+ kit as recommended by the manufacturer (Qiagen). First-strand cDNA was synthesized using random primers (Promega) and SuperScriptIII reverse transcriptase (Invitrogen). Quantitative PCR was performed on StepOne Real-Time PCR System (Applied Biosystems) with DyNAmo HS SYBR Green supermix (Finnzymes) and ROX as a passive reference dye. Reactions were carried out in one-piece thin-wall 48-well PCR plates (Bioplastics). GAPDH mRNA was used as a normalization standard. Primers 5'-CCATGGACGTCTTCAAGAAAGG-3' and 5'-CGTTCTCCTTGGTTTTGGTG-3' were used for amplification of gamma-synuclein cDNA, and primers 5'-CACTGAGCATCTCCCTCACA-3' and 5'-GTGGGTGCAGCGAACTTTAT-3' for amplification of GAPDH mRNA. After hot start (10 min at 95degreesC), 40 cycles of 15 s at 95degreesC and 60 s at 60degreesC were carried out followed by melting curve determination with 0.3degreesC steps. Fold change was determined by 2-DeltaDeltaCT method as described previously (70) using StepOne v2.0 software.
###end p 62
###begin title 63
Protein extraction
###end title 63
###begin p 64
###xml 220 221 214 215 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 245 246 239 240 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 402 403 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
Total tissue proteins were extracted by homogenization of tissues directly in SDS-PAGE loading buffer followed by incubation for 10 min at 100degreesC. For analysis of cytosolic proteins, tissues were homogenized in 50 mm Tris-HCl, pH 7.5; 150 mm NaCl; 1% Triton X-100 buffer with protease inhibitors (Complete Mini from Roche) and cytosolic fraction was obtained by centrifugation for 10 min at 10 000g.
###end p 64
###begin title 65
Sequential protein extraction
###end title 65
###begin p 66
###xml 33 35 33 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C37">37</xref>
###xml 158 159 158 159 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 183 184 183 184 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 194 195 194 195 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
A previously described protocol (37) was used with minor modifications. Briefly, neuronal tissues were homogenized in 5 volumes of high salt (HS) buffer (50 mm Tris-HCl, pH 7.5; 750 mm NaCl; 5 mm EDTA) with protease inhibitors (Complete Mini from Roche) and centrifuged at 100 000g for 20 min at 4degreesC. Pellets were washed in the same buffer and then re-extracted in HS buffer containing 1% Triton X-100 (HS/T-soluble fraction). Subsequent centrifugations and re-extractions produced RIPA-soluble and SDS-soluble fractions. The presence of gamma-synuclein in these fractions was analysed by SDS-PAGE/western blotting.
###end p 66
###begin title 67
Isolation and visualization of gamma-synuclein filaments
###end title 67
###begin p 68
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C71">71</xref>
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 172 173 172 173 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 417 419 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C31">31</xref>
###xml 688 690 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C72">72</xref>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 368 374 <span type="species:ncbi:9986">rabbit</span>
###xml 380 385 <span type="species:ncbi:10090">mouse</span>
###xml 464 468 <span type="species:ncbi:9925">goat</span>
###xml 474 480 <span type="species:ncbi:9986">rabbit</span>
Sarcosyl-insoluble filaments were extracted from mouse spinal cords as described previously for human neuronal tissues (71). Final 100 000g pellets were resuspended in 50 mm Tris-HCl (pH 7.5) buffer and aliquots were applied onto glow-discharged carbon-coated 400-mesh copper grids. After blocking in 1% BSA/PBS, grids were incubated in 1:50 diluted affinity purified rabbit anti-mouse gamma-synuclein SK23 antibody (31) for 60 min at room temperature followed by goat anti-rabbit immunoglobulin secondary antibody (Amersham) conjugated to 10 nm gold particles. Fibrils were negatively stained with 1% dodeca-tungstophosphoric acid neutralized with KOH to pH 6.2 as described previously (72) and observed at x40 000 or x50 000 magnification under a Philips TEM 208 transmission electron microscope.
###end p 68
###begin title 69
Western blotting and antibodies
###end title 69
###begin p 70
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C31">31</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C68">68</xref>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
###xml 548 553 <span type="species:ncbi:10090">mouse</span>
###xml 623 628 <span type="species:ncbi:10090">mouse</span>
###xml 698 704 <span type="species:ncbi:9986">rabbit</span>
###xml 748 754 <span type="species:ncbi:9986">rabbit</span>
###xml 781 786 <span type="species:ncbi:10090">mouse</span>
###xml 833 836 <span type="species:ncbi:10116">rat</span>
###xml 881 887 <span type="species:ncbi:9986">rabbit</span>
###xml 918 923 <span type="species:ncbi:10090">mouse</span>
###xml 987 993 <span type="species:ncbi:9986">rabbit</span>
###xml 1037 1043 <span type="species:ncbi:9986">rabbit</span>
###xml 1100 1106 <span type="species:ncbi:9986">rabbit</span>
Proteins separated by SDS-PAGE were transferred to PVDF membrane using iBlot technology according to manufacturer (Invitrogen) instructions. Membrane blocking, incubation with antibodies, washing and chemiluminescent detection using ECL or ECL+ techniques were carried out as described previously (31,68). Intensities of bands obtained using AlphaImager 2200 were analysed using AlphaEase 2200 Analysis Software (AlphaInnotech Corporation). Primary antibodies against GAPDH (mouse monoclonal, clone 6C5, Santa Cruz Biotechnology), alpha-synuclein (mouse monoclonal, clone 42, BD Transduction Laboratories), beta-synuclein (mouse monoclonal, clone 8, BD Transduction Laboratories), gamma-synuclein (rabbit polyclonal SK23, affinity purified), GFAP (rabbit polyclonal, Sigma), Iba1 (mouse monoclonal, clone 1022-5, Santa Cruz), CD11b (rat monoclonal, clone M1/70.15, Serotec), NF-L (rabbit monoclonal, clone C28E10, and mouse monoclonal, clone DA2, both Cell Signalling), neurofilament H (rabbit polyclonal, Sigma), heat shock protein B1 (rabbit monoclonal, Cell Signalling) and heat shock protein 70 (rabbit monoclonal, Cell Signalling) were used.
###end p 70
###begin title 71
Immunoprecipitation
###end title 71
###begin p 72
###xml 100 101 100 101 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 125 126 125 126 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 138 139 138 139 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 144 145 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 441 442 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 777 778 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 479 484 <span type="species:ncbi:10090">mouse</span>
###xml 575 581 <span type="species:ncbi:9986">rabbit</span>
Freshly dissected spinal cords from individual animals were homogenized in 0.5 ml of IP buffer (50 mm Tris-HCl, pH 7.5, 300 mm NaCl, 1.5 mm MgCl2, 1% Triton X-100) with protease inhibitors (Complete Mini from Roche) and Triton-soluble fraction was obtained by x10 000g centrifugation for 10 min at 4degreesC. After presorption on Protein G Sepharose (Amersham) for 30 min at 4degreesC and removal of beads by centrifugation for 1 min at 1000g, 5 microl of antibody against NF-L (mouse monoclonal, clone DA2, Cell Signalling) or 20 microl of antibody against gamma-synuclein (rabbit polyclonal SK23) were added, followed by 50 microl of fresh Protein G Sepharose. The suspension was rotated at 4degreesC for 2 h Sepharose beads were collected by centrifugation for 1 min at 1000g and washed four times with IP buffer. Bound proteins were eluted by boiling beads in 50 microl of SDS-PAGE loading buffer for 10 min.
###end p 72
###begin title 73
Histological techniques
###end title 73
###begin p 74
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDP090C32">32</xref>
###xml 818 819 818 819 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 984 985 984 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1161 1162 1161 1162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Dissected tissues were post-fixed in 4% paraformaldehyde/PBS or Carnoy's fixative and embedded in paraffin wax. Eight micrometre thick sections were cut and immunostained as described previously (32) using Elite plus kits (Vector laboratories) and 3,3'-diaminobenzidine as a substrate. For double immunofluorescence, secondary Alexa Fluor-conjugated antibody (Invitrogen) were used. Images were prepared using laser scanning confocal microscope Leica TCS SP2 (Leica Microsystems) and LEICA CONFOCAL 2.00 software. For detection and counting of amyloid aggregates, spinal cord sections (four to five animals per age/genotype/condition group) were stained in 0.5% Congo red solution in 50% ethanol for 7 min followed by a brief differentiation in potassium hydroxide (0.2% in 80% ethanol) and, after several washes in dH2O, were mounted using Immu-mount (Thermo Electron Corporation). Fluorescent microscopy was used to analyse the number of aggregates within a randomly selected 0.1 mm2 area of the spinal cord gray matter. For assessing number of spinal motor neurons, transverse spinal cord sections were stained in 0.5% cresyl fast violet (CFV) solution in dH2O and dissociated in acidified ethanol (0.25% acetic acid in ethanol). The number of motor neurons (identified by a large cell body containing Nissl granules, with a clear nuclear envelope containing a strongly stained nucleolus) within the ventral horn was counted. Results were expressed as per cent of the average number of motor neurons per ventral horn section in the wild-type animals.
###end p 74
###begin title 75
SUPPLEMENTARY MATERIAL
###end title 75
###begin p 76

###end p 76
###begin title 77
FUNDING
###end title 77
###begin p 78
###xml 27 45 27 45 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The Wellcome Trust</grant-sponsor>
###xml 60 66 60 66 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">075615</grant-num>
This work was supported by The Wellcome Trust [grant number 075615]. Funding to pay the Open Access publication charges for this article was provided by The Wellcome Trust.
###end p 78
###begin title 79
Supplementary Material
###end title 79
###begin title 80
[Supplementary Data]
###end title 80
###begin title 81
ACKNOWLEDGEMENTS
###end title 81
###begin p 82
We are grateful to K.H. Wiederhold, Simone Danner, Sabine Kauffmann, Chiara Mencarelly, Abdelmojib Al-Wandi and Robert Durkin for preliminary analysis done at an early stage of this project; Matthias Mueller and Bernd Kinzel for help in generating the transgenic lines; Anthony Hann and Simon Brooks for valuable advices and Rosalind John for critical reading of the manuscript.
###end p 82
###begin p 83
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 83
###begin title 84
REFERENCES
###end title 84
###begin article-title 85
Cell systems and the toxic mechanism(s) of alpha-synuclein
###end article-title 85
###begin article-title 86
Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease
###end article-title 86
###begin article-title 87
Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease
###end article-title 87
###begin article-title 88
Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides
###end article-title 88
###begin article-title 89
beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor
###end article-title 89
###begin article-title 90
Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression
###end article-title 90
###begin article-title 91
An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model
###end article-title 91
###begin article-title 92
Residual structure, backbone dynamics, and interactions within the synuclein family
###end article-title 92
###begin article-title 93
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease
###end article-title 93
###begin article-title 94
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease
###end article-title 94
###begin article-title 95
Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs
###end article-title 95
###begin article-title 96
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins
###end article-title 96
###begin article-title 97
###xml 53 58 <span type="species:ncbi:9606">human</span>
Sequence determinants for amyloid fibrillogenesis of human alpha-synuclein
###end article-title 97
###begin article-title 98
Induction of neuronal death by alpha-synuclein
###end article-title 98
###begin article-title 99
Persyn, a member of the synuclein family, influences neurofilament network integrity
###end article-title 99
###begin article-title 100
Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve
###end article-title 100
###begin article-title 101
Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease
###end article-title 101
###begin article-title 102
Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes
###end article-title 102
###begin article-title 103
Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate gyrus
###end article-title 103
###begin article-title 104
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology
###end article-title 104
###begin article-title 105
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
###end article-title 105
###begin article-title 106
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
Discrete gene sets depend on POU domain transcription factor Brn3b/Brn-3.2/POU4f2 for their expression in the mouse embryonic retina
###end article-title 106
###begin article-title 107
###xml 57 60 <span type="species:ncbi:10116">rat</span>
Distribution of alpha- and gamma-synucleins in the adult rat brain and their modification by high-dose cocaine treatment
###end article-title 107
###begin article-title 108
###xml 106 111 <span type="species:ncbi:10090">mouse</span>
Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model
###end article-title 108
###begin article-title 109
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma
###end article-title 109
###begin article-title 110
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse
###end article-title 110
###begin article-title 111
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 34 39 <span type="species:ncbi:9606">human</span>
Neuropathology in mice expressing human alpha-synuclein
###end article-title 111
###begin article-title 112
###xml 46 61 <span type="species:ncbi:10090">transgenic mice</span>
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters
###end article-title 112
###begin article-title 113
Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration
###end article-title 113
###begin article-title 114
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 59 64 <span type="species:ncbi:9606">human</span>
Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease
###end article-title 114
###begin article-title 115
Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system
###end article-title 115
###begin article-title 116
Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene
###end article-title 116
###begin article-title 117
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein
###end article-title 117
###begin article-title 118
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders
###end article-title 118
###begin article-title 119
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 160 175 <span type="species:ncbi:10090">transgenic mice</span>
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice
###end article-title 119
###begin article-title 120
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 39 44 <span type="species:ncbi:9606">human</span>
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation
###end article-title 120
###begin article-title 121
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 85 90 <span type="species:ncbi:9606">human</span>
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein
###end article-title 121
###begin article-title 122
###xml 74 89 <span type="species:ncbi:10090">transgenic mice</span>
Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice
###end article-title 122
###begin article-title 123
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein
###end article-title 123
###begin article-title 124
Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression
###end article-title 124
###begin article-title 125
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice
###end article-title 125
###begin article-title 126
Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis
###end article-title 126
###begin article-title 127
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model
###end article-title 127
###begin article-title 128
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein
###end article-title 128
###begin article-title 129
Disruption of neurofilament network with aggregation of light neurofilament protein: a common pathway leading to motor neuron degeneration due to Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1
###end article-title 129
###begin article-title 130
Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy
###end article-title 130
###begin article-title 131
A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes
###end article-title 131
###begin article-title 132
Mechanisms and models of alpha-synuclein-related neurodegeneration
###end article-title 132
###begin article-title 133
In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?
###end article-title 133
###begin article-title 134
Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies-is the juice worth the squeeze?
###end article-title 134
###begin article-title 135
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration
###end article-title 135
###begin article-title 136
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
###end article-title 136
###begin article-title 137
Hsp70 reduces alpha-synuclein aggregation and toxicity
###end article-title 137
###begin article-title 138
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model
###end article-title 138
###begin article-title 139
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice
###end article-title 139
###begin article-title 140
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies
###end article-title 140
###begin article-title 141
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies
###end article-title 141
###begin article-title 142
Neuronal intermediate filaments and ALS: a new look at an old question
###end article-title 142
###begin article-title 143
Functions of intermediate filaments in neuronal development and disease
###end article-title 143
###begin article-title 144
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse models of amyotrophic lateral sclerosis
###end article-title 144
###begin article-title 145
Unraveling the mechanisms involved in motor neuron degeneration in ALS
###end article-title 145
###begin article-title 146
Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation
###end article-title 146
###begin article-title 147
Phenotypic analysis of neurofilament light gene mutations linked to Charcot-Marie-Tooth disease in cell culture models
###end article-title 147
###begin article-title 148
A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene
###end article-title 148
###begin article-title 149
Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E
###end article-title 149
###begin article-title 150
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
Formation of intermediate filament protein aggregates with disparate effects in two transgenic mouse models lacking the neurofilament light subunit
###end article-title 150
###begin article-title 151
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Temporal profiles of neuronal degeneration, glial proliferation, and cell death in hNFL(+/+) and NFL(-/-) mice
###end article-title 151
###begin article-title 152
###xml 191 195 <span type="species:ncbi:10090">mice</span>
Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice
###end article-title 152
###begin article-title 153
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
###end article-title 153
###begin article-title 154
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method
###end article-title 154
###begin article-title 155
Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
###end article-title 155
###begin article-title 156
Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation
###end article-title 156

